Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1
- 1 April 2020
- journal article
- research article
- Published by Elsevier BV in Laboratory Investigation
- Vol. 33 (9), 1678-1689
- https://doi.org/10.1038/s41379-020-0531-2
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaBlood, 2016
- RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic featuresLeukemia, 2016
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaThe New England Journal of Medicine, 2013
- RUNX1 Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study GroupJournal of Clinical Oncology, 2011
- RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosisBlood, 2011
- Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AMLLeukemia, 2010
- AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterationsBlood, 2009
- RUNX1 gene mutation in primary myelodysplastic syndrome – the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcomeBritish Journal of Haematology, 2007
- High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasiaBlood, 2004
- Hematologic malignanciesCurrent Opinion in Hematology, 2001